Edition:
United States

Tigenix NV (TIG.OQ)

TIG.OQ on NASDAQ Stock Exchange Global Select Market

21.67USD
14 Dec 2017
Change (% chg)

$-2.54 (-10.49%)
Prev Close
$24.21
Open
$23.28
Day's High
$23.36
Day's Low
$20.59
Volume
24,406
Avg. Vol
3,160
52-wk High
$25.72
52-wk Low
$10.77

Chart for

About

TiGenix NV is a Belgium-based biopharmaceutical company focused on the development and commercialization of therapeutics from its platforms of allogeneic, or donor-derived, expanded stem cells. The Company's two products from the adipose-derived stem cell platform are in clinical development. Cx601 is in Phase III for the... (more)

Overall

Beta: -0.66
Market Cap(Mil.): €293.21
Shares Outstanding(Mil.): 274.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion

* REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE

Dec 15 2017

BRIEF-Tigenix Nv - Mesoblast Grants Access To Patents To Support Commercialization Of Adipose-Derived Mesenchymal Stem Cell Product Cx601 For Treatment Of Fistulae​

* - MESOBLAST GRANTS ACCESS TO PATENTS TO SUPPORT COMMERCIALIZATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELL PRODUCT CX601 FOR TREATMENT OF FISTULAE​

Dec 14 2017

BRIEF-JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​

* ‍JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​ Source text for Eikon: Further company coverage:

Nov 24 2017

BRIEF-Tigenix announces approval of trade name for CX601 in Europe

* TIGENIX ANNOUNCES APPROVAL OF TRADE NAME FOR LEAD DEVELOPMENT CANDIDATE CX601 IN EUROPE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 16 2017

BRIEF-Tigenix announces partial conversion of bonds

* ‍ANNOUNCES CONVERSION OF EUR 7 MILLION OF COMPANY'S SENIOR UNSECURED CONVERTIBLE BONDS DUE 2018​

Nov 06 2017

BRIEF-Tigenix obtains patent for Cx601 lead development program

* REG-TIGENIX STRENGTHENS EUROPEAN IP PROTECTION AROUND LEAD DEVELOPMENT PROGRAM CX601

Nov 02 2017

BRIEF-TiGenix provides update on Cx601 marketing authorization application

* REG-TIGENIX PROVIDES REGULATORY UPDATE ON CX601 EU MARKETING AUTHORIZATION APPLICATION PROCEDURE

Oct 31 2017

BRIEF-TiGenix granted orphan drug designation from FDA for CX601

* REG-TIGENIX GRANTED ORPHAN DRUG DESIGNATION FROM THE U.S. FDA FOR CX601 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 23 2017

BRIEF-Tigenix granted orphan drug designation from the U.S. FDA for CX601

* Tigenix granted orphan drug designation from the U.S. FDA for cx601

Oct 23 2017

BRIEF-Tigenix H1 operating loss widens to 20.5 million euros

* H1 OPERATING LOSS EUR 20.5 MILLION VERSUS LOSS OF EUR 13.1 MILLION YEAR AGO

Sep 19 2017

Earnings vs. Estimates